Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...

Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced it has submitted supplementary chemical composition and biocompatibility data to the U.S. Food and Drug Administration (FDA) in support of the Company’s Virtis pre-market approval (PMA) application for the treatment of chronic urinary retention and symptoms of overactive bladder. Fred Parks, Chief Executive Officer, commented, “In April of this year, the FDA requested additional information on chemical composition and biocompatibility regarding our Virtis PMA application. Today, with all requested studies favorably concluded, we submitted the results to the FDA and believe we have fully satisfied their request for supplemental toxicity and biocompatibility data.

Q2 2018 Nuvectra Corp Earnings Call

Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

Axonics (AXNX) expects to improve performance on the positive outcome of the study.

PLANO, Texas, June 12, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that members of management are scheduled to.

Q2 2019 Nuvectra Corp Earnings Call

'Big Short' investor’s top holdings include 3 retail companies Continue reading...

If you own shares in Nuvectra Corporation (NASDAQ:NVTR) then it's worth thinking about how it contributes to the...

Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019 after market close. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 3264026.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics ...

The big shareholder groups in Nuvectra Corporation (NASDAQ:NVTR) have power over the company. Insiders often own a...

Nuvectra (NVTR) delivered earnings and revenue surprises of 23.46% and -0.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced the appointment of Jennifer Kosharek as Chief Financial Officer, effective September 16, 2019. Ms. Kosharek will assume the role of Chief Financial Officer after having served as the Company’s interim Chief Financial Officer since May 2019, leveraging over fifteen years of audit and accounting experience and various finance and leadership positions within Nuvectra. Dr. Fred Parks, Nuvectra’s Chief Executive Officer, commented, "I am pleased that Jennifer has assumed the role of Chief Financial Officer on a permanent basis.

Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced that its Board of Directors has decided to explore potential strategic alternatives to enhance shareholder value. The Company is currently evaluating all options, including a sale or merger of the Company, to finance the expected growth of the Nuvectra business.

Nuvectra Corporation (NVTR) (“Nuvectra” or the “Company”), a neurostimulation medical device company, today announced that it has elected to file a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Court”). The Company intends to use this Court-supervised process to continue its review of a range of options to maximize value and address its financial obligations.

PLANO, Texas, July 31, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended.

It's nice to see the Nuvectra Corporation (NASDAQ:NVTR) share price up 27% in a week. But that doesn't change the fact...